Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer
January 03 2022 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the
"Company”), today announces the appointment of Dr. Boyan Litchev,
M.D., as Chief Medical Officer, effective January 31, 2022. Dr.
Litchev will oversee clinical strategy, clinical development and
the conduct of all clinical programs and will report directly to
Jeffrey A. Meckler, Chief Executive Officer of Indaptus.
“We are delighted to welcome Boyan to the
Indaptus team,” said Mr. Meckler. “During 2021, we transitioned
Indaptus into a cutting-edge company based on a new medical
modality and this appointment underscores the progress we’ve made
and the potential for our novel technology. We look forward to 2022
under Dr. Litchev’s stewardship as we plan to initiate clinical
studies of Decoy20. His diverse experience, including both as an
oncology clinical researcher and executive leader, will provide
important insights as we advance our pipeline from the bench to the
bedside over the coming years.”
“This is an exciting time to join Indaptus, as
the Company embarks on initiating first-in-human clinical trials
with its promising proprietary platform that is designed to
activate both the innate and adaptive cellular immune pathways to
treat various human diseases,” said Dr. Litchev. “I look forward to
working with the team and bringing my skillsets and experience as
we advance this novel approach towards developing new medicines for
patients with some of the highest unmet medical needs.”
Dr. Litchev brings significant experience across
a multitude of medical leadership roles that are specifically
relevant for Indaptus. Before joining Indaptus, Dr. Litchev served
as Senior Vice President and Head of Global Clinical Development
Oncology at Shoreline Biosciences. Before that, he was Head of
Clinical Development Oncology, Medical Affairs and Safety at
Poseida Therapeutics, where he led all activities related to CAR-T
programs in solid tumors. In addition, he has held similar
executive medical positions at Halozyme, Akcea Therapeutics (now
Ionis Pharmaceuticals), Baxalta/Baxter/Shire (now Takeda), and
Ferring Pharmaceuticals. Earlier, Dr. Litchev was a Clinical Team
Leader, Oncology at Quintiles International (now IQVIA). Prior to
that he practiced as a physician and clinical researcher. Dr.
Litchev holds an M.D. degree from Medical University Plovdiv.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company's approach is
based on the hypothesis that efficient activation of both innate
and adaptive immune cells and associated anti-tumor and anti-viral
immune responses will require a multi-targeted package of immune
system activating signals that can be administered safely
intravenously. Indaptus' patented technology is composed of single
strains of attenuated and killed, non-pathogenic, Gram-negative
bacteria, with reduced i.v. toxicity, but largely uncompromised
ability to prime or activate many of the cellular components of
innate and adaptive immunity. This approach has led to broad
anti-tumor and anti-viral activity, including safe, durable
anti-tumor response synergy with each of five different classes of
existing agents, including checkpoint therapy, targeted antibody
therapy and low-dose chemotherapy in preclinical models. Tumor
eradication by Indaptus technology has demonstrated activation of
both innate and adaptive immunological memory and, importantly,
does not require provision of or targeting a tumor antigen in
pre-clinical models. Indaptus has carried out successful GMP
manufacturing of its lead clinical oncology candidate, Decoy20, and
is currently completing other IND enabling studies.
Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management's
expectations, beliefs and intentions regarding, among other things,
our product development efforts, business, financial condition,
results of operations, strategies, plans and prospects.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause our
actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many
factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: Indaptus' plans to develop and potentially commercialize
its technology, the timing and cost of Indaptus' planned
investigational new drug application and any clinical trials, the
completion and receiving favorable results in any clinical trials,
Indaptus' ability to obtain and maintain regulatory approval of any
product candidate, Indaptus' ability to protect and maintain its
intellectual property and licensing arrangements, Indaptus' ability
to develop, manufacture and commercialize its product candidates,
the risk of product liability claims, the availability of
reimbursement, the influence of extensive and costly government
regulation, and Indaptus' estimates regarding future revenue,
expenses capital requirements and the need for additional financing
following the merger. These risks, as well as other risks are
discussed in the proxy statement/prospectus that was included in
the registration statement on Form S-4 filed with the SEC in
connection with the merger. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Investor Contact:Will O'Connor Stern
Investor Relations +1
212-362-1200 will.oconnor@sternir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024